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Nonsteroidal antiinflammatory drugs alter antibiotic susceptibility and expression of
virulence-related genes and protein A of Staphylococcus aureus
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Background/aim: Nonsteroidal antiinflammatory drugs (NSAIDs) including diclofenac, naproxen, ibuprofen, acetylsalicylic acid, and
acetaminophen have been shown to have antimicrobial effects on various microorganisms. The aim of this study was to investigate the
antibacterial effects of NSAIDs on Staphylococcus aureus.
Materials and methods: Susceptibilities of S. aureus strains to NSAIDs with or without antimicrobials (moxifloxacin, vancomycin,
ciprofloxacin, clindamycin, and gentamicin) were determined using the microdilution method and disk diffusion test. Expression levels
of genes in the presence of drugs were investigated by real-time quantitative RT-PCR (qRT-PCR), and immunoblotting analysis was
performed for staphylococcal protein A (SpA).
Results: Our results showed that all NSAIDs were active against S. aureus strains with MIC values ranging from 195 µg/mL to 6250 µg/
mL. NSAIDs increased the antibiotic susceptibility of the strains, and diclofenac was found to be more effective than the other drugs.
Drugs showed different effects on expression levels of virulence factor and/or regulatory genes. Immunoblotting analysis of SpA protein
was mostly in accordance with qRT-PCR results.
Conclusion: The regulatory/virulence factor genes and proteins of S. aureus investigated in this study may be reasonable targets for
these drugs, and we suggest that the data may contribute to the field of infection control and antimicrobial resistance.
Keywords: Gene expression, nonsteroidal antiinflammatory drugs, Staphylococcus aureus, antibiotic sensitivity, real-time qRT-PCR,
immunoblotting

1. Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) clones
were first detected in European hospitals during the 1960s.
MRSA rapidly spread across international borders, and is
now increasingly recognized in the community [1,2]. MRSA
has emerged as a cause of various community-associated
infections in both pediatric and adult populations from rural
and urban areas [1,3]. MRSA strains have become resistant
to many beta-lactam agents, macrolides, aminoglycosides,
and lincosamides [1,4]. As a result of resistance, vancomycin
usage has increased, and more recently, emergence of
vancomycin-intermediate and vancomycin-resistant S.
aureus strains have become problematic [5]. In recent
decades, MRSA has acquired a dramatic relevance in
human medicine for different reasons and still continues
to be a major cause of health care-related and communityassociated infections with multidrug-resistant strains [6,7].

Staphylococcus aureus has diverse components
and products that contribute to the pathogenesis of
infection, and these factors can act together or alone [8].
Staphylococcus aureus produces a variety of pyrogenic
toxins and super-antigens, and forms biofilms on tissues
and medical devices, which cause drug resistance and
difficulty in treatment [4,6]. It is not possible to describe
the vast majority of S. aureus infections with the effect of a
single virulence component, indeed it is likely that a number
of virulence factors, including toxins, cell wall-associated
adhesins, and secreted exoproteins, can act in combination
in the process of diseases [9]. The accessory gene regulator
(agr), staphylococcal accessory regulator (sar), multidrug
efflux pump gene repressor (mgr) and sigma factor B
(sigB) have been identified as regulatory genes in S. aureus
coordinating the expression of various groups of virulence
factors. Staphylococcal protein A (SpA), a 42 kDa surface
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protein, represents an important virulence factor that has
the ability to interact with immune system components
including immunoglobulin (Ig) molecules. SpA is
covalently anchored to the cell wall of most S. aureus strains
and contains highly homologous extracellular Ig-binding
domains in tandem [10–12]. Multidrug efflux is one of the
critical mechanisms responsible for resistance in S. aureus
via removal of drug from its site of action. Multidrug and
toxin extrusion (MATE) family multidrug efflux pump
(MepA) is a member of multidrug resistance-conferring
efflux pumps that are based on structural characteristics
and energy requirements [13]. Sortase (SrtA), a membrane
protein in S. aureus, is a thiol transpeptidase that tethers
cell surface components to the cell wall [14,15]. Expression
of virulence genes may have clinical importance, and
different stages of infections appear to require different
expression patterns of virulence determinants [1,16].
Antibiotics, antiinflammatory, analgesic, and antipyretic
drugs are used in the treatment of bacterial infections
and inflammation, alone or in combination. The term
“nonantibiotic” was coined by Kristiansen [17] for certain
drugs that have a greater/lesser degree of broad-spectrum
antibacterial activity, and most studies have focused on
nonsteroidal antiinflammatory drugs (NSAIDs) [18].
The aim of this study was to investigate the antibacterial
effects of frequently used antiinflammatory, analgesic,
and antipyretic drugs on clinical and nonclinical S.
aureus strains. For this purpose, antibacterial effects of
diclofenac, naproxen, ibuprofen, acetylsalicylic acid,
and acetaminophen were evaluated using phenotypic
methods. The effects of these drugs on the expression of
genes (sarA, agrRNAIII, sigB, mgrA, spa, mepA, and srtA)
and SpA were also investigated using transcriptional and
protein experiments.
2. Materials and methods
2.1. Bacterial strains and chemicals
The present study utilized three clinical MRSA isolates
(MRSA#1, MRSA#2, and MRSA#3) from navel swab,
tracheal aspirate and biopsy sample, and S. aureus
ATCC 29213 strain. Clinical isolates were obtained
from the department of clinical microbiology, faculty of
medicine, Ege University, İzmir. Bacteria were stored in
brain-heart infusion broth (Merck KGaA, Darmstadt,
Germany) with 10% glycerin at 
80 °C. Moxifloxacin
(Bayer Türk Chemistry, İstanbul, Turkey), vancomycin
(Mustafa Nevzat Pharmaceuticals, İstanbul, Turkey),
ciprofloxacin, clindamycin, gentamicin (İ. E. Ulagay
Pharmaceuticals, İstanbul, Turkey), diclofenac, naproxen,
ibuprofen (Abdi İbrahim Pharmaceuticals, İstanbul,
Turkey), acetylsalicylic acid and acetaminophen (Bayer
Türk Chemistry) were provided by the pharmaceutical
companies. Stock solutions of NSAIDs and antimicrobials
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were prepared in dimethylsulfoxide (DMSO) and distilled
water, respectively, and filter-sterilization (0.2 μm) (Merck
KGaA) was performed.
2.2. Disk diffusion test
Inhibition zone diameters of the drugs on bacteria were
determined with the disk diffusion method according
to the recommendations of the Clinical and Laboratory
Standards Institute (CLSI) [19]. Staphylococcus aureus
ATCC 25923 was used as a control strain. Bacteria were
grown on Mueller–Hinton Agar (MHA) (Merck KGaA)
at 37 °C for 24 h. Bacterial suspensions were prepared
with physiological saline solution and cell densities were
adjusted to 0.5 McFarland turbidity with densitometer
(Den-1, Biosan SIA, Riga, Latvia). Bacterial suspensions
were spread on MHA plates, and sterile empty discs (6
mm in diameter, Oxoid, UK) were placed on inoculated
plates. Ten microliters of each of the drugs (100 μg/disk)
were added onto the disks, and plates were incubated
at 37 °C overnight. Cefoxitin antibiotic discs (30 µg,
Oxoid Germany GmbH, Wesel, Germany) were used as
a reference. Each sample was studied in triplicate, and
quality control ranges were evaluated according to CLSI
criteria. The diameters of inhibition zones were measured
after the incubation period and mean values were reported.
2.3. Microdilution method
Minimum inhibitory concentration (MIC) values of
the drugs were determined by microdilution method
as suggested by CLSI [19]. Staphylococcus aureus ATCC
29213 was used as control strain. Bacterial suspensions
were prepared with fresh colonies grown on MHA
overnight. Suspensions were adjusted to 0.5 McFarland
and diluted at a ratio of 1:100 (vol/vol). Fifty microliters
of cation-adjusted MuellerHinton broth (Merck KGaA)
were pipetted in each well of sterile 96-well plates. Fifty
microliters of drug solutions were added to the first
wells and serial dilutions of drugs were performed. Fifty
microliter suspensions of bacteria were added to the wells,
and plates were incubated at 37 °C for 24 h. Each drug was
tested in triplicate; the lowest concentration that prevented
microbial growth visually was determined as the MIC
value, and quality control ranges were evaluated according
to CLSI criteria.
2.4. MIC alteration experiments
Effects of NSAIDs (100 μg/μL) on MICs of the
antimicrobials were performed using the microdilution
method as mentioned above with minor modification.
The drug solutions (40 μL) were added to the first wells,
and serial dilutions were performed. Each drug solution
(10 μL) was added to the wells at final concentrations of
100 μg/μL. All the experiments were done in triplicate, and
mean values were calculated.
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2.5. Real-time qRT-PCR
2.5.1. Preparation of inoculum and drug treatment
conditions
Bacterial suspensions (0.5 McFarland) were inoculated
in Luria–Bertani (LB) broth (Merck KGaA) with sterile
swabs and incubated with orbital shaking (Thermo Fisher,
MaxQ 6000, Thermo Fisher Scientific Inc.,Waltham, MA,
USA) (200 rpm) at 35°C for 4 h. Samples were transferred
to sterile tubes and incubated with orbital shaking (200
rpm) with final concentrations of agents at 100 μg/μL and
MICs for incubation periods of 4 and 16 h. All treatment
procedures were carried out for three biological replicates.
The optical density of bacterial cells was adjusted to equal
levels.
2.5.2. RNA isolation and cDNA synthesis
One milliliter of each bacterial suspension was centrifuged,
and total RNA was isolated from pellets using GeneJET
RNA Purification Kit (Thermo Fisher Scientific Inc.)
according to manufacturer’s instructions. Total RNA
concentrations were calculated by measuring absorbance
at 260 nm (nanoVette, Beckman Coulter, Indianapolis,
IN, USA). Two nanograms of each total RNA were used
to synthesize cDNA using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA). The cDNA samples were diluted 1/50. All reactions
were performed in triplicate.
2.5.3. Real-time qRT-PCR
To determine the effects of NSAIDs on mRNA expression
levels of spa, sarA, agrRNAIII, sigB, mepA, mgrA, and

srtA genes, real-time qRT-PCR was performed using
LightCycler 480 Instrument II (Roche, USA). Reactions
were carried out in a 96-well plate using LightCycler
480 SYBR Green I Master kit (Roche Molecular Systems,
Branchburg, NJ, USA). Primer sequences are given in
Table 1. Housekeeping 16S rRNA gene was used as a
control to normalize data. PCR was as follows: 5 min at
95 °C for initial denaturation, followed by 45 cycles of
denaturation at 95 °C for 10 s, annealing at 43 °C for 10
s and elongation at 72 °C for 10 s before melting curve
analysis. Threshold cycle (CT) values were calculated
using the LC480 2 software program. All expression levels
were normalized to that of internal 16S rRNA and given as
target gene/16S rRNA. Data are presented as a fold change
in gene expression in the presence of NSAIDs compared to
control groups using delta delta CT method. All samples
were analyzed in triplicate.
2.6. Protein isolation and immunoblotting analysis
2.6.1. Preparation of inoculum and total protein isolation
Preparation of cell extracts was performed with some
modification of previously published protocol [20]. One
milliliter of each bacterial suspension was centrifuged at
5.000 × g at 10 °C. Pellets were suspended in 1 mL fresh
buffer A (20 mMTris-HCl, pH 7.5, 150 mMNaCl, 5%
glycerol, and 100 µg/mL lysostaphin), and the cells were
incubated at 42 °C for 5 min. Sonication was performed
for 10 s with 30% power (Bandelin Sonopuls, Bandelin
Electronic, Berlin, Germany), and suspensions were
centrifuged at 10000 × g for 45 min to remove cell debris.

Table 1. Primers used for real time qRT-PCR study.
Primer
16S rRNA
spa
agr RNAIII
sarA
srtA
mepA
sigB
mgrA

Sequence (5’-3’)
F: TCGTGTCGTGAGATGTTG
R: CTGCCCTTTGTATTGTCC
F: TATGCCTAACTTAAATGCTG
R: TTGGAGCTTGAGAGTCATTA
F: GGGATGGCTTAATAACTCATA
R: GGAAGGAGTGATTTCAATGG
F: CATCAGCGAAAACAAAGAGAAA
R: TTCTTTCATCATGCTCATTACGTT
F: CTTATCCTAGTGGCAGCATATTTGT
R: TGAGGTTTAGCTTGCTGCTT
F: GCGTTGGTGCAGGAACTTAT
R: GCTGCGATTTGATCACTGAA
F: TTTCACCTGAGCAAATTAACCA
R: TCTTCGTGATGTGATTGTCCTT
F: CAATGCTCAAAGACAAGTTAATCG
R: TCTTGACGTTTACAGGAGATTCA

Amplicon
(bp)

Reference

188

[23]

119

[22]

174

[22]

146

[23]

146

[39]

151

[24]

145

[23]

122

[23]
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3. Results
3.1. Antimicrobial activity
Antimicrobial effects of the drugs were determined using
disk diffusion and broth microdilution methods. Mean
inhibition zone diameters of drugs for standard strain
and clinical isolates are shown in Table 2. Inhibition
zones were obtained with diclofenac and ibuprofen with
the volume of 100 µg per disk for all studied bacteria in
the disk diffusion test. Diclofenac was found to have the
highest inhibition zone diameters. The results obtained
for standard strain and clinical isolates are presented in
Table 2. All the tested drugs were active against studied
bacteria with MIC values from 195 µg/mL to 6250 µg/mL.
Resistance profiles and the MICs of antibiotics show that
MRSA#1 isolate was resistant to clindamycin (MIC: 20 µg/
mL), MRSA#2 isolate was resistant to clindamycin (MIC:
20 µg/mL) and intermediate susceptible to ciprofloxacin
(MIC: 1.25 µg/mL), MRSA#3 isolate was resistant to
moxifloxacin (MIC: 2.5 µg/mL), ciprofloxacin (MIC: 80
µg/mL), clindamycin (MIC: 10 µg/mL) and gentamicin
(MIC: 80 µg/mL).
Effects of the drugs (100 µg/mL) on susceptibility of
isolates to several antibiotics were determined using the
microdilution method with 25 combinations, and new
MIC values of antibiotics in the presence of the drugs
are demonstrated in Table 3. The presence of diclofenac
resulted in a 4-fold (MRSA#1), 3.33-fold (MRSA#2) and
2-fold (MRSA#3) decrease in MICs of ciprofloxacin,
6.66-fold decrease in MICs of clindamycin and 6.66fold (MRSA#1 and MRSA#2) and 5.6-fold (MRSA#3)
decrease in MICs of gentamicin against three MRSA
isolates. The presence of ibuprofen and naproxen resulted
in a 6.66-fold decrease in MICs of gentamicin against
MRSA#1. Ibuprofen and naproxen also reduced MICs of
gentamicin 5.33-fold/8-fold in MRSA#2 and 4-fold / 4.8fold in MRSA#3, respectively. MICs of gentamicin were
reduced 4-fold in MRSA#1 and MRSA#2 in the presence
of acetaminophen while MIC of gentamicin was reduced
2-fold in the presence of acetylsalicylic acid in MRSA#3.

2.6.2. SDS-PAGE and immunoblotting
The concentration of total protein was determined with
standard protein bovine serum albumin (BCA) (SigmaAldrich Chemie GmbH, Taufkirchen, Germany) using
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
Rockford, IL, USA). Each sample was adjusted to equal
concentrations, and one-dimensional denaturing sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) was performed with 10% polyacrylamide gels in a
Bio-Rad Protean-II electrophoresis system. Total proteins
were separated on 12% SDS-PAGE gel and transferred onto
nitrocellulose membranes, membranes were reversibly
stained with Ponceau S as a loading control. Membranes
were washed three times for 10 min with TBS buffer (10
mMTris-HCl, 150 mMNaCl, pH 7.5) and incubated for 1 h
in blocking buffer (5% BSA, 0.1% Tween 20 in TBS buffer).
Membranes were washed three times for 10 min in TBSTween-Triton buffer (20 mMTris-HCl, 500 mMNaCl, 0.05%
Tween 20, 0.2% Triton X-100, pH 7.5). Membranes were
then incubated with primer antistaphylococcal protein A
(antispA) antibody (Novus Dahle GmbH, Lingen, Germany)
solutions (1:1000) at 4 °C overnight. Membranes were washed
three times for 10 min in TBS-Tween-Triton buffer and
incubated with secondary antibodies (Goat anti-,,,rabbit IgG
(H+L) Secondary Antibody, HRP, Thermo Fisher Scientific,
Rockford, IL, USA) (1:7500) for 1 h at room temperature.
Membranes were washed three times for 10 min in TBSTween-Triton. Super Signal West Pico Chemiluminescent
Substrate kit (Thermo Fisher Scientific, Fockford, IL, USA)
was used for chemiluminescence detection according to
the manufacturer’s recommendations, and the Fusion FX-7
program was used with the imaging device (Vilber Lourmat,
Collégien, France). All samples were analyzed at least in
triplicate and representative images of these triplicates are
given in the figures.
2.7. Statistical analysis
Statistical significance between the means of two groups
was evaluated using t-test and P ≤ 0.05 was considered
significant. Statistical analyses were performed using the
GraphPad Prism 5 program.

Table 2. Mean inhibition zone diameters (mm) and MICs (µg/mL) of NSAIDs.

Strains

ASA

ACE

DIC

IBU

NAP

mm

µg/mL

mm

µg/mL

mm

µg/mL

mm

µg/mL

mm

µg/mL

MRSA#1

-

780

-

6250

14.3

390

7.3

780

-

780

MRSA#2

-

780

-

6250

14

390

7.3

780

-

780

MRSA#3

-

780

-

6250

15.7

195

7

780

-

780

ATCC

-

390

-

6250

17.3

195

7.7

780

-

780

ASA: acetylsalicylic acid, ACE: acetaminophen, DIC: diclofenac, IBU: ibuprofen, NAP: naproxen, (-): no
inhibition zone.
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Table 3. Effects of NSAIDs on the MICs of the antibiotics
(fold-change decrease in the MICs of antibiotics, *: fold-change
increase).

Drugs

Bacteria
MRSA#1

MRSA#2

MRSA#3

ATCC

MOX+ASA

-

-

-

1.25

MOX+ACE

-

-

-

1.25

MOX+DIC

1.33

1.66

-

1.25

MOX+IBU

-

-

-

1.25

MOX+NAP

-

-

1.66

1.25

CIP+ASA

-

-

-

-

CIP+ACE

-

1.66

-

1.66

CIP+DIC

4

3.33

2

4

CIP+IBU

-

-

-

*1.2

CIP+NAP

-

-

-

*1.2

VAN+ASA

-

1.33

1.33

-

VAN+ACE

-

-

-

-

VAN+DIC

2.33

-

-

1.66

VAN+IBU

1.33

-

1.33

-

VAN+NAP

2

-

2

2

CLI+ASA

-

-

-

-

CLI+ACE

1.66

1.66

1.66

-

CLI+DIC

6.66

6.66

6.66

2.33

CLI+IBU

-

3.33

-

-

CLI+NAP

-

2.66

-

-

GEN+ASA

1.33

1.66

2

1.25

GEN+ACE

4

4

1.6

1.25

GEN+DIC

6.66

6.66

5.6

2.5

GEN+IBU

6.66

5.33

4

3

GEN+NAP

6.66

8

4.8

2.5

MOX: moxifloxacin, CIP: ciprofloxacin, VAN: vancomycin, CLI:
clindamycin, GEN: gentamicin, (-): no alteration, the data was
the mean of three replicates.

3.2. Gene expression analysis by real-time qRT-PCR
Real-time qRT-PCR results are expressed as n-fold
alteration in the expression of the genes (sarA, agr RNAIII,
sigB, mgrA, spa, mepA, and srtA) versus 16S rRNA in the
presence of drugs relative to without drugs. We observed
that the addition of NSAIDs caused alteration in each gene
expression levels at different rates. The addition of 100 μg/
mL drugs to cultures of bacteria resulted in significant
downregulation in the expression of three genes (sigB,
mepA, and mgrA) in two isolates. For instance, mepA
gene expression in MRSA#1 was downregulated 4.8-fold

and 5.9-fold after 16 h incubation in the presence of 100
μg/mL acetylsalicylic acid and naproxen, respectively.
Downregulation of mepA (12.7-fold), sigB (8.3-fold)
and mgrA (8.4-fold) was also observed with 100 μg/mL
ibuprofen with 4 h incubation in MRSA#2. In addition,
100 μg/mL diclofenac incubation for 4 h resulted in
significant downregulation in the expression of sigB (3.1fold) and mgrA (3.7-fold) in MRSA#2 although slight
upregulation of sarA (1.8-fold), sigB (1.6-fold), mepA (2.4fold), and mgrA (2.7-fold) was observed in MRSA#3 after
16 h incubation in the presence of 100 μg/mL diclofenac.
The addition of drugs at MIC levels to the cultures
of bacteria with 4 h and 16 h incubation resulted in
significant alterations on the expression levels of the genes
(Table 4). Our results revealed that sigB, mepA, mgrA,
and srtA were downregulated in MRSA#1; and spa, sigB,
and srtA were downregulated in MRSA#2, in response
to growth with acetylsalicylic acid at MIC levels for 4 h
and 16 h. In response to growth with acetaminophen at
MIC levels for 4 h and 16 h, sigB, mgrA, and srtA genes
were downregulated in MRSA#1; spa, sigB, and srtA
were downregulated in MRSA#2, and only mgrA was
downregulated in MRSA#3 in our analysis. The addition
of diclofenac at MIC levels to the cultures for 4 h and 16
h resulted in a significant downregulation of srtA and
spa in MRSA#1 and MRSA#2, respectively. Growth of
MRSA#1 in the presence of ibuprofen at MIC for 4 h and
16 h downregulated the expression of sigB, mepA, mgrA,
and srtA. In contrast to the downregulation of the genes
in the presence of acetylsalicylic acid and acetaminophen,
spa, sigB, mgrA, and srtA genes were upregulated following
16 h of growth in the presence of ibuprofen at MIC level
in ATCC strain. In addition, mepA and srtA genes were
also downregulated in MRSA#1; spa and srtA genes were
downregulated in MRSA#2 in the presence of naproxen at
MIC for 4 h and 16 h.
3.3. Immunoblotting
Staphylococcus aureus has many virulence factors
including toxins, cell wall-associated adhesins and
secreted exoproteins, and these proteins can act in the
process of several diseases. SpA protein, encoding by spa
gene, represents an important role in interfering with host
defence, and expression of SpA on the cell surface can
cause bacteria less susceptible to host immune system.
As shown in Table 5, in our experiments, we evaluated
the effects of the drugs on SpA protein expression levels
using immunoblotting, following drug treatment, total
protein quantification, and SDS-PAGE. We examined
samples where spa gene expression levels were found to
be upregulated or downregulated in the presence of drugs.
Immunoblotting analyses in SpA protein expression
mostly correlates with the findings of significantly reduced
transcriptional activity of the drugs (Table 5). In parallel, a
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16 h

4h

-

-

NAP

11.8
(0.004)

-

ACE

IBU

5.4
(0.007)

-

ASA

-

-

-

8.3
(0.033)

-

23.8
(˂0.001)

NAP

-

5.7
(0.04)

-

28.9
(˂0.001)

IBU

DIC

-

-

-

-

-

-

-

-

4.6
(0.029)

-

2.5/5.9
(0.003/0.031)

-

4.6
(0.043)

9.2
(˂0.001)

9
(0.022)

-

13.3
(0.026)

-

13
(˂0.001)

6.1/4.8
6.6
(˂0.001/0.034) (0.034)

6.2
(0.031)

12.3
(0.022)

-

-

12.9
(0.02)

7.1
(0.025)

5
(˂0.001)

9
(˂0.001)

-

2.2
(0.003)

4.6
(0.034)

3.2
(0.004)

3.2
(0.013)

-

3.14
(0.016)

1.7
(0.026)
7.2
(0.001)

12.7
(0.003)

8
(0.004)

6.1
(0.006)

26.5
(0.002)

2.1
(0.015)

21.4
(0.002)

14.7
(0.001)

6.7
(0.001)

7.1
(0.001)

9.1
(0.001)

2.2
(0.012)

3.4
(0.009)

17.9
(0.002)

7.2
(˂0.001)

-

5.8
(0.001)

6.6
(0.001)

DIC

-

4.7
(0.027)

-

6.5
(0.028)

27.7
(˂0.001)

5.6
(˂0.001)

ACE

-

-

-

-

-

-

-

5.1
(0.031)

-

9.9
(0.024)

6.4
(0.036)

sarA

-

srtA

15
(˂0.001)

mgrA

ASA

mepA

spa

sigB

sarA

spa

RNAIII

Genes of MRSA#2

Genes of MRSA#1

Drugs and
incubation
time

-

-

-

-

-

-

-

-

-

-

RNAIII

10.1
(0.027)

-

8.9
(0.029)

30.4
(0.021)

10.1
(0.027)

-

-/3.1
(0.006)
9/8.3
(0.017/
0.007)

11.8
(0.016)

5.9
(0.027)

sigB

-

-

8.4
(0.048)

25.9
(0.036)

16
(0.039)

-

13.3
(0.011)

-

10.3
(0.012)

31.4
(0.009)

15.4
(0.01)

-

-/8.4
(0.007)

-/12.7
(0.012)

10.1
(0.005)

-

6.4
(0.007)

24.3
(0.003)

13.8
(0.004)

10.8
(0.02)

20.3
(0.017)

-

-/3.7
(0.014)
-

8.4
(0.023)

srtA

8.8
(0.022)

-

mgrA

-

-

-

mepA

Table 4. Effects of the drugs at MIC on the expression of the genes significantly (P ≤ 0.05) after 4 h and 16 h incubation (fold-change downregulation and P values, *: fold-change
upregulation).
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mepA

mgrA

srtA

-

NAP

-

ACE

-

-

ASA

IBU

-

NAP

-

-

IBU

DIC

-

-

ACE

DIC

-

-

-

-

-

-

-/*1.8
(0.032)

-

-

-/*1.6
(0.044)

-

2.8
(0.024)

3.8
(0.005)

11.8
(0.01)

-

3.2
(0.007)

6.3
(0.013)

-

-

-/*2.4
(0.042)

-

-

-

3.7
(0.005)

6
(0.015)
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-/*2.7
(0.04)

-

-

-

-

-

1.9
(0.01)
2.6
(0.003)

11.3
(0.011)

6.4
(0.015)

-

4
(0.027)

-

5
(0.006)

6.2
(0.005)

-

4.4
(0.009)

-

-

-

*5.4
(0.047)
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

sarA

-

-

-

-

-

-

-

-

-

-

RNAIII

-

*23.1
(0.031)

-

2.8
(0.021)

2.7
(0.018)

-

-

-

-

-

sigB

MIC: minimum inhibitory concentration, (-): no alteration, (bold): alteration with 100 µg/mL drugs, the data was the mean of three replicates.

16 h

4h

sigB

spa

RNAIII

spa

sarA

Genes of ATCC strain

Genes of MRSA#3

ASA

Drugs and
incubation
time

Table 4. (Continued).

*24.4
(0.03)
-

2
(0.009)

-

3.7
(0.011)

3.7
(0.007)

-

-

-

-

-

mgrA

-

-

6.4
(˂0.001)

3.7
(0.004)

-

-

-

-

-

mepA

-

*27
(0.032)

-

2.9
(0.042)

-

-

-

-

-

-

srtA
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Table 5. Alterations in the expression of spa gene and SpA protein after
incubation for 4 h and 16 h in the presence of the drugs at MICs.

ASA
ACE
DIC
IBU
NAP

MRSA#1

MRSA#2

MRSA#3

ATCC

spa

SpA

spa

SpA

spa

SpA

spa

SpA

4h

↓

↓

↓

↓

-

nt

-

nt

16 h

-

nt

↓

-

-

nt

-

nt

4h

↓

↓

↓

↓

-

nt

-

nt

16 h

-

nt

↓

-

-

nt

-

nt

4h

↓

↓

↓

↓

-

nt

-

nt

16 h

-

nt

↓

↓

-

nt

-

nt

4h

↓

↓

↓

↓

-

nt

-

nt

16 h

-

nt

↓

↓

-

nt

↑

↑

4h

↓

↓

↓

↓

-

nt

-

nt

16 h

-

nt

↓

↓

-

nt

-

nt

spa: staphylococcal protein A gene, SpA: staphylococcal protein A, (-): no
alteration, (↓): downregulation, (↑): upregulation, nt: not tested.

decrease in SpA levels versus control group (DMSO group)
was observed in two of four strains (MRSA#1: Figures 1A
and 1B, MRSA#2: Figures 2A–2D).
A strong decrease in SpA of MRSA#1 and MRSA#2 was
determined in the presence of some drugs at MICs after
4 h incubation compared to control groups. Diclofenac,
ibuprofen, and naproxen caused a strong decrease in SpA
expression level of MRSA#2 at MIC after 4h and 16 h of
incubation. Acetylsalicylic acid and acetaminophen had
no inhibitory effect in the expression of SpA in MRSA#2
although expression of spa gene was decreased in the same
treatment conditions. In contrast to these findings, an
increase in SpA expression was determined in ibuprofentreated cells of ATCC strain after 16 h incubation as
compared with the untreated group (Figures 3A and 3B).
4. Discussion
In literature, it has been observed that the number of studies
investigating the effects of NSAIDs and antimicrobials on
various groups of bacterial virulence factors are limited
[21–24]. In some studies, NSAIDs have been found to
alter susceptibility of bacteria to antimicrobials [23,24].
Antimicrobial effects have been reported as most likely acting
on multiple targets, and have been revealed by targeting
DNA biosynthesis and replication, regulation of adhesins,
toxins, biofilm and several metabolism pathways, and
physiochemical effects on bacterial membrane [23–28]. In
this study, we investigated antibacterial effects of frequently
used NSAIDs, and alterations in antibiotic susceptibility
were studied by phenotypic methods before the experiments
investigating the gene and protein expression levels.
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According to the results of phenotypic experiments
including the disk diffusion test, our results indicate
that inhibition zones were obtained with diclofenac and
ibuprofen. Thus, we noticed that antimicrobial activity
test methods including water-based media in the presence
of the substances that are insoluble or less soluble in
water, lower the potential antimicrobial effects because
of solubility and diffusion issues. In a study, Obad et al.
evaluated antimicrobial activity of ibuprofen as pure
substance, salt, and lysine form in different formulations
with disk diffusion tests and obtained inhibition zones for
S. aureus ATCC strain with more than 62.5 and 250 µg
of ibuprofen/disk and ibuprofen lysine/disk, respectively
[29]. In another study, Laudy et al. investigated the effects
of NSAIDs on bacterial susceptibility to antibiotics and
modulation of bacterial efflux pumps and determined the
activity of the drugs against clinical gram-negative bacteria
by microdilution method [30]. Laudy et al. demonstrated
that MICs of diclofenac, acetylsalicylic acid, ibuprofen,
and paracetamol were between the range of 800 and
3200 µg/mL against clinical isolates. Al-Janabi reported
that clinical S. aureus and Paracoccus yeei isolates were
found to be susceptible to ibuprofen and acetaminophen
at 1250 µg/mL concentration [31]. In addition, MIC
values of diclofenac sodium were determined between
the ranges of 50 and 100 µg/mL against various S. aureus
strains in previous studies [25,32,33]. In this study, we
observed inhibition zones with 100 µg/disk of ibuprofen
and diclofenac against standard strain and three clinical
MRSA isolates, and we observed low MIC values with the
addition of NSAIDs against clinical gram-positive bacteria
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Figure 1. Western blot for detection of SpA of MRSA#1 isolate
after treatment of the drugs at MICs for 4 h incubation (A).
Ponceau S staining of the blot (B). DMSO: dimethyl sulfoxide.
All samples were analyzed in triplicate and representative images
of these triplicates are given.

when compared to other results involving MICs against
clinical strains.
The presence of NSAIDs mostly resulted in a decrease
in MICs of antibiotics. In previous studies, it has been
reported that active ingredients of salicylate and acetyl
salicylate may be effective in the increase of resistance
rates to fluoroquinolones, and despite the growth in the
presence of salicylate may reduce MICs of some antibiotics
[34,35]. Importantly, we demonstrated that acetylsalicylic
acid slightly reduced MICs of gentamicin and moxifloxacin
in both gentamicin susceptible and resistant S. aureus
strains. Riordan et al. examined susceptibility of eight
S. aureus strains to seven antibiotics in the presence
of diclofenac using agar diffusion and drug gradient
plate analysis [24]. They revealed that 32 and 64 μg/mL
diclofenac increased susceptibility of S. aureus strains to
quinolones (ciprofloxacin, norfloxacin, and ofloxacin)
in a concentration and strain-dependent manner.
Moreover, their results showed that diclofenac decreased
susceptibility of S. aureus to oxacillin and vancomycin, but
did not alter MICs for chloramphenicol or tetracycline.
In this study, in parallel with findings of Riordan et al.
[24], diclofenac resulted in 2-fold to 4-fold decrease in
MICs of ciprofloxacin including MICs of ciprofloxacin in
intermediate and resistant isolates. We also demonstrated
that diclofenac decreased MICs of various antibiotics
such as moxifloxacin, vancomycin, clindamycin, and
gentamicin. Furthermore, we found that the presence of
ibuprofen and naproxen resulted in a decrease in MICs
of gentamicin against S. aureus strains. Additionally, we
showed that MICs of gentamicin were reduced in two
isolates in the presence of acetaminophen, and the MIC
of gentamicin was reduced in one isolate in the presence
of acetylsalicylic acid. Moreover, MICs of gentamicin
were decreased in the presence of diclofenac, ibuprofen,
and naproxen in resistant MRSA#3 isolate. Although
it has been indicated that the growth in the presence of
these NSAIDs can be both beneficial and detrimental,
our results suggest that the presence of these drugs may

Figure 2. Western blots for detection of SpA of MRSA#2 isolate
after treatment of the drugs at MICs for 4 h (A) and 16 h (C)
incubation. Ponceau S staining of the blots (B and D). All samples
were analyzed in triplicate and representative images of these
triplicates are given.

Figure 3. Western blot for detection of SpA of ATCC strain after
treatment of ibuprofen at MIC for 16 h incubation (A). Ponceau
S staining of the blot (B). All samples were analyzed in triplicate
and representative images of these triplicates are given.

result in a decrease in MICs of several antibiotics. Thus
the effects of drugs on susceptibility to several antibiotics
have been determined in detail, and the effects of drugs on
transcriptome/protein A alterations described in S. aureus.
Global regulatory genes of staphylococci coordinate
expression of various groups of genes, and expression rates
may have clinical importance. Staphylococcal infections
appear to require different combinations of virulence
determinants in different stages of infections. Expression of
surface proteins favors colonization of host tissues, whereas
synthesis of exoproteins favors the spread to adjacent
tissues [8]. Regulatory genes can alter the expression
rates of many genes (such as enzymes, toxins, cell wall
surface adhesives etc.) associated with virulence factors,
either directly or inversely. Since several genes related to
virulence factors are likely to be produced in very low
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amounts in bacteria, the detection of these genes at RNA
and protein levels is more difficult than regulatory and
structural genes, and regulatory genes were predominantly
preferred in our experiments. In this study, the effects of
the drugs differed among the agents, and our findings
on transcriptional activity of drugs mostly correlate with
findings of immunoblotting analyses. In addition, our
results suggest that the alterations in the expression of
certain genes altered expression rates of related genes in
a similar way, and they are thought to interact with each
other when compared with the downregulation rates.
The downregulation of spa gene was found to be
parallel to SpA protein by the majority of our experiments.
Although the downregulation in mRNA expression
levels of spa gene in a clinical isolate were determined in
the presence of drugs for 16 h, we were unable to detect
an alteration in the expression of SpA protein in two
acetylsalicylic acid-treated and acetaminophen-treated
samples under our experimental conditions. Additionally,
we demonstrated the downregulation of spa gene and SpA
protein expression levels in two ibuprofen-treated clinical
isolates. Interestingly, parallel to the upregulation rates
of spa gene, an increase in SpA protein was determined
in ibuprofen-treated cells of nonclinical ATCC strain
after 16 h incubation compared with untreated group.
We suggest that, in addition to the impact on spa gene,
ibuprofen can mediate an impact on the upregulation and
downregulation of different regulatory and virulencerelated genes including sigB, mgrA, and srtA as shown in the
results of our transcriptional experiments. Kupferwasser
et al. also reported an increase of SpA protein and spa gene
expression levels in salicylic acid-treated cells of S. aureus
[36].
It is known that SpA has the ability to interact with the
host components, including the immune system, and the
expression of SpA on the bacterial cell surface can cause
the bacteria to be less susceptible to phagocytosis. In this
study, parallel to the findings on spa gene, we demonstrated
that the expression of srtA gene was downregulated in the
presence of NSAIDs, and the expression levels depended
on the drugs and treatment time. In addition to the role
of SpA, SrtA may have an important role in the virulence
of S. aureus including the bacterial adhesion to host
tissues and evasion of host immune components directly
and/or indirectly. Newly discovered inhibitors of SpA
and SrtA proteins may act as antimicrobials and may
affect pathogenesis of bacterial infections with several
mechanisms of action.
The sigB is a global stress regulon, it has been indicated
in many studies that sigB negatively regulates the function
of several adhesin genes and leads to repression of sarA
and agr global regulons in S. aureus. Kupferwasser et al.
investigated antivirulence properties of salicylic acid in S.
aureus strains [36]. They demonstrated that sarA and agr
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were mitigated by salicylic acid in vitro, corresponding
to the reduced expression of hla and fnbA genes. They
also confirmed the key roles of sarA and sigB in vivo, in
mediating antistaphylococcal effects in experimental
endocarditis. Kupferwasser et al. reported a mean increase
of SpA levels (17.6% ± 3.9%) in S. aureus strains exposed
to 50 µg/mL salicylic acid [36]. They also reported a
corresponding 2-fold increase in spa gene expression in
salicylic acid-treated cells. In contrast, we demonstrated
that spa gene expression was downregulated in two of
four strains in response to growth with acetylsalicylic
acid. In this study, we reported that the expression of spa
gene was upregulated only in the presence of ibuprofen.
Our immunoblotting analyses in SpA protein expression
mostly correlate with the findings of transcriptional
analyses. Interestingly, our results revealed that sigB,
sarA, and agrRNAIII were downregulated in MRSA#1 in
the presence of acetylsalicylic acid and acetaminophen;
and sigB and sarA were downregulated in MRSA#2 in
the presence of acetylsalicylic acid, acetaminophen, and
ibuprofen at MICs. Our results suggest that, while sigB
negatively regulates sarA and agr global regulons in low
concentrations, the presence of studied drugs at high levels
may eliminate the suppressive effect of sigB.
MgrA (also known as Rat or NorR) is one of the SarA
paralogs that are involved in the regulation of sarA family
genes and virulence genes, and the SarA-SarR pathway
may be involved in positive regulation of agr transcription
in the exponential phase of growth [37]. It is also known
that mgrA is involved in positive regulation of agr
transcription in S. aureus, and a mutation in mgrA resulted
in altered expression of agr RNAIII, sarS, hla, and spa
genes [38]. Ingavale et al. reported that mgrA had a dual
role in regulating hla and spa expression, and decreased
agr transcription in mgrA mutants led to reduced hla
transcription and an increase in spa transcription [38].
Riordan et al. investigated the transcriptome alterations
and physiological responses that occurred in S. aureus cells
exposed to 2 mM sodium salicylate [23]. They reported the
downregulation of mgrA and sarR (repressor of sarA gene)
and upregulation of antibiotic target genes such as parE and
fusA [23]. In this study, we demonstrated that a decrease
in mgrA transcription in the presence of acetylsalicylic
acid and acetaminophen led to downregulation in the
expression of sarA and agr RNAIII in isolate MRSA#1.
We also reported that the downregulation of mgrA gene
led to decreased expression of spa gene and SpA protein
in the presence of acetylsalicylic acid, acetaminophen, and
ibuprofen in MRSA#1, and in the presence of diclofenac and
naproxen in MRSA#2. In this study, parallel to the findings
of Riordan et al., S. aureus strains did not demonstrate
increased resistance to ciprofloxacin and other antibiotics
[23]. It is known that mgrA is a repressor of efflux pump
genes, and we speculate that studied drugs can be effective
in the decrease of MIC levels of fluoroquinolones and
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other group of antibiotics via mgrA-independent pathway.
Transcriptome alterations in S. aureus strain were
described in addition to the alterations in susceptibilities
when grown with diclofenac [24]. Riordan et al. suggested
that diclofenac altered the expression of regulatory/
structural genes associated with cell wall biosynthesis/
turnover and transport [24]. They reported that diclofenac
induction led to the downregulation of mepA and mepB,
revealing that the mepRAB operon was being repressed
in the presence of diclofenac. It is known that mepA gene
encodes MATE family efflux pump, and we demonstrated
that the MIC of ciprofloxacin was reduced 2-fold in
one isolate in the presence of 100 µg/mL diclofenac.
Interestingly, mepA gene was upregulated in one isolate
in the presence of 100 µg/mL diclofenac, although the
expression rates were downregulated or not altered in
the presence of several drugs. As a consequence, we also
speculate that diclofenac can demonstrate increased
susceptibility to ciprofloxacin by mepA-independent
pathway.
In conclusion, our results indicate that studied
NSAIDs may hold promise as new agents for preventing
and reducing the severity of infections caused by S. aureus.

Our findings demonstrate that the targeting of regulatory/
virulence genes and protein A may be a reasonable
strategy in the field of infection control and antimicrobial
resistance. More experimentation will be required to
investigate the understanding of the mechanism of gene/
protein regulation in bacterial strains by NSAIDs.
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